MinorProgestogen-only pill (POP)×Low-molecular-weight heparin (LMWH)
Updated · Methodology
Mechanism
Enoxaparin sodium is a low-molecular-weight heparin. In the liver, it is broken down by desulfation and depolymerisation into fragments with much lower activity, and the kidneys excrete about 40% of the dose as active and inactive fragments (enoxaparin SmPC). Desogestrel is converted to its active metabolite etonogestrel, which is then metabolised mainly by hepatic CYP3A (desogestrel SmPC). The elimination pathways do not overlap. Hormonal contraceptives are not among the drugs affecting haemostasis that are not recommended or need caution with enoxaparin. Anticoagulants are not among the drugs that change desogestrel levels or are affected by it (enoxaparin and desogestrel SmPCs; Lovenox label, US Food and Drug Administration, FDA). No document names the pair.
Symptoms
The documents describe no symptoms linked to this combination. Enoxaparin can cause bleeding at any site. Between days 5 and 21 of treatment, it can cause immune-mediated thrombocytopenia, suggested by new thromboses, painful skin lesions at the injection site or allergic reactions (enoxaparin SmPC). Desogestrel often causes irregular bleeding: it was reported by up to 50% of women, and in some the bleeding becomes more frequent or longer (desogestrel SmPC). Combined hormonal contraceptives are linked to venous thrombosis, but the clinical relevance of these data for desogestrel without an oestrogen is unknown (desogestrel SmPC).
Management
According to the documents, the combination is acceptable, and the doses of enoxaparin and desogestrel need no change. Hormonal contraceptives are not on the list of drugs to stop before enoxaparin or to use with caution alongside it (enoxaparin SmPC; Lovenox label, US Food and Drug Administration, FDA). Desogestrel is contraindicated in active venous thromboembolism and is stopped if thrombosis occurs. Stopping it is considered during long-term immobilisation due to surgery or illness (desogestrel SmPC). A woman with previous thromboembolism should take the possibility of recurrence into account (desogestrel SmPC). Undiagnosed vaginal bleeding is a contraindication to desogestrel, and any bleeding during enoxaparin treatment calls for a search for its source (desogestrel and enoxaparin SmPCs). Count platelets before enoxaparin starts and periodically after that, and stop enoxaparin at once if the count falls by 30–50% from baseline (enoxaparin SmPC). Women weighing less than 45 kg on prophylactic enoxaparin doses are monitored closely because exposure and bleeding risk increase (enoxaparin SmPC; Lovenox label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Enoxaparina sódica, Clexane 10.000 UI (100 mg)/1 ml (nº registro 62472), sección 4.5 (2022)– AEMPS, CIMA, nº registro 62472 (Clexane 10.000 UI (100 mg)/1 ml solución inyectable en jeringa precargada, Sanofi Aventis), revisión del texto 02/2022, ficha técnica en CIMA del 07/10/2022, secciones 4.2, 4.4, 4.5 y 5.1
- AEMPS: Ficha técnica: Desogestrel, Cerazet 75 microgramos (nº registro 62285), sección 4.5 (2021)– AEMPS, CIMA, nº registro 62285 (Cerazet 75 microgramos comprimidos recubiertos con película, Organon Salud), revisión del texto 11/2020, ficha técnica en CIMA del 26/03/2021, secciones 4.3, 4.4, 4.5 y 5.2
- FDA: Lovenox (enoxaparin sodium) prescribing information (2026)– FDA, DailyMed setid 5017a927-2a24-4f27-89f9-27c805bf7d59 (Sanofi-Aventis U.S., NDA 020164), version 33, 05/2026, sections 5.1, 5.4, 5.5, 7 and 8.8